BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23817438)

  • 1. Amyloid deposition and cognition in older adults: the effects of premorbid intellect.
    Duff K; Foster NL; Dennett K; Hammers DB; Zollinger LV; Christian PE; Butterfield RI; Beardmore BE; Wang AY; Morton KA; Hoffman JM
    Arch Clin Neuropsychol; 2013 Nov; 28(7):665-71. PubMed ID: 23817438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between
    Hammers DB; Atkinson TJ; Dalley BC; Suhrie KR; Beardmore BE; Burrell LD; Horn KP; Rasmussen KM; Foster NL; Duff K; Hoffman JM
    Clin Neuropsychol; 2017 Apr; 31(3):531-543. PubMed ID: 28077020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change on the Repeatable Battery for the Assessment of Neuropsychological Status and its relationship to brain amyloid.
    Duff K; Dixon AM; Embree L; Hoffman JM
    J Clin Exp Neuropsychol; 2023 Mar; 45(2):105-117. PubMed ID: 37224404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
    Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
    Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Premorbid Scores on the Repeatable Battery for the Assessment of Neuropsychological Status and their Validation in an Elderly Sample.
    Duff K; Dalley BCA; Suhrie KR; Hammers DB
    Arch Clin Neuropsychol; 2019 May; 34(3):395-402. PubMed ID: 29878036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of [
    Leuzy A; Savitcheva I; Chiotis K; Lilja J; Andersen P; Bogdanovic N; Jelic V; Nordberg A
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1276-1286. PubMed ID: 30915522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.
    Rosenberg PB; Wong DF; Edell SL; Ross JS; Joshi AD; Brašić JR; Zhou Y; Raymont V; Kumar A; Ravert HT; Dannals RF; Pontecorvo MJ; Skovronsky DM; Lyketsos CG
    Am J Geriatr Psychiatry; 2013 Mar; 21(3):272-8. PubMed ID: 23395194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age.
    van Bergen JMG; Li X; Quevenco FC; Gietl AF; Treyer V; Meyer R; Buck A; Kaufmann PA; Nitsch RM; van Zijl PCM; Hock C; Unschuld PG
    Neuroimage; 2018 Jul; 174():308-316. PubMed ID: 29548847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.
    Tosun D; Schuff N; Mathis CA; Jagust W; Weiner MW;
    Brain; 2011 Apr; 134(Pt 4):1077-88. PubMed ID: 21429865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premorbid intellect and current RBANS performance: discrepancy scores in three geriatric samples.
    Duff K; Schoenberg MR; Beglinger LJ; Moser DJ; Bayless JD; Culp KR; Carnahan R; Mold JW; Scott JG; Adams RL
    Appl Neuropsychol; 2008; 15(4):241-9. PubMed ID: 19023741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults.
    Hammers DB; Atkinson TJ; Dalley BCA; Suhrie KR; Horn KP; Rasmussen KM; Beardmore BE; Burrell LD; Duff K; Hoffman JM
    Am J Alzheimers Dis Other Demen; 2017 Sep; 32(6):320-328. PubMed ID: 28403622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.
    Kreisl WC; Lyoo CH; McGwier M; Snow J; Jenko KJ; Kimura N; Corona W; Morse CL; Zoghbi SS; Pike VW; McMahon FJ; Turner RS; Innis RB;
    Brain; 2013 Jul; 136(Pt 7):2228-38. PubMed ID: 23775979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.